Roy L - Search Results

1

Comprehensive characterization of a novel intronic pseudo-exon inserted within an e14/a2 BCR-ABL rearrangement in a patient with chronic myeloid leukemia.

Sorel N, Mayeur-Rousse C, Deverrière S, Roy L, Brottier-Mancini E, Guilhot F, Turhan AG, Chomel JC. Sorel N, et al. Among authors: roy l. J Mol Diagn. 2010 Jul;12(4):520-4. doi: 10.2353/jmoldx.2010.090218. Epub 2010 May 27. J Mol Diagn. 2010. PMID: 20508029 Free PMC article.

2

Interferon therapy in chronic myelogenous leukemia.

Guilhot F, Roy L, Guilhot J, Millot F. Guilhot F, et al. Among authors: roy l. Hematol Oncol Clin North Am. 2004 Jun;18(3):585-603, viii. doi: 10.1016/j.hoc.2004.03.002. Hematol Oncol Clin North Am. 2004. PMID: 15271394 Review.

3

Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia.

Roy L, Guilhot J, Martineau G, Larchée R, Guilhot F. Roy L, et al. Leukemia. 2005 Sep;19(9):1689-92. doi: 10.1038/sj.leu.2403874. Leukemia. 2005. PMID: 16015386 No abstract available.

4

Reply to 'Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib' by Pilot et al.

Roy L, Guilhot J, Martineau G, Guilhot F. Roy L, et al. Leukemia. 2006 Jan;20(1):149. doi: 10.1038/sj.leu.2404027. Leukemia. 2006. PMID: 16281065 No abstract available.

5

Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.

Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA, O'Brien S, So C, Massimini G, Guilhot F. Roy L, et al. Blood. 2006 Sep 1;108(5):1478-84. doi: 10.1182/blood-2006-02-001495. Epub 2006 Apr 20. Blood. 2006. PMID: 16627756 Free article.

6

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP).

Nicolini FE, Corm S, Lê QH, Sorel N, Hayette S, Bories D, Leguay T, Roy L, Giraudier S, Tulliez M, Facon T, Mahon FX, Cayuela JM, Rousselot P, Michallet M, Preudhomme C, Guilhot F, Roche-Lestienne C. Nicolini FE, et al. Among authors: roy l. Leukemia. 2006 Jun;20(6):1061-6. doi: 10.1038/sj.leu.2404236. Leukemia. 2006. PMID: 16642048

7

Sequential emergence of ABL-kinase mutations with loss of unmutated BCR-ABL allele during targeted therapies of CML.

Sorel N, Roy L, Martineau G, Guilhot F, Turhan AG, Chomel JC. Sorel N, et al. Among authors: roy l. Blood. 2006 Sep 1;108(5):1782-3. doi: 10.1182/blood-2006-03-011668. Blood. 2006. PMID: 16926302 Free article. No abstract available.

8

Immunotherapy in chronic myelogenous leukemia.

Guilhot F, Roy L, Martineua G, Guilhot J, Millot F. Guilhot F, et al. Among authors: roy l. Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S64-70. doi: 10.3816/clm.2007.s.004. Clin Lymphoma Myeloma. 2007. PMID: 17382015 Review.

9

Immunotherapeutic approaches in chronic myelogenous leukemia.

Guilhot F, Roy L, Saulnier PJ, Guilhot J, Barra A, Gombert JM, Turhan A. Guilhot F, et al. Among authors: roy l. Leuk Lymphoma. 2008 Apr;49(4):629-34. doi: 10.1080/10428190801927510. Leuk Lymphoma. 2008. PMID: 18398723 Review.

10

Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).

Chomel JC, Sorel N, Bonnet ML, Bertrand A, Brizard F, Saulnier PJ, Roy L, Guilhot F, Turhan AG. Chomel JC, et al. Among authors: roy l. Leuk Res. 2009 Apr;33(4):551-5. doi: 10.1016/j.leukres.2008.08.018. Epub 2008 Sep 30. Leuk Res. 2009. PMID: 18829107

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

979 results

Search Page

Filters